FORM 4

Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549	
-------------	------------	--

Check this box if no longer subject	
to Section 16. Form 4 or Form 5	
obligations may continue. See	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-0287									
	Estimated average burden									
ı	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Topsoe Christina Teng						2. Issuer Name and Ticker or Trading Symbol IGM Biosciences, Inc. [ IGMS ]								plicable) ctor	2	X 10%	Owner
(Last) (First) (Middle) C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD							t Trans	action (	(Month	n/Day/Year)				e 		r (specify v)	
				4. If A	Line) X Form file									n filed by C n filed by M	filed by One Reporting Persor		
1. Title of Security (Instr. 3)  2. Transaction Date					on 2A. Deemed Execution Date,			3. 4. Securities Acquired (A)			ed (A) or	5. Amo Securit Benefic Owned	unt of ies cially Following	at of 6. Ow Form (D) o ollowing (I) (In		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Transa	Transaction(s) (Instr. 3 and 4)			(moan ly
Common Stock 09/30/20					021			A		195(1)	A	\$0.0	0 36	36,388		D	
Common Stock													10,4	00,564		I	See footnote <sup>(2)</sup>
	Tal	ble II												ed			
	3. Transaction Date (Month/Day/Year)	Execu if any	tion Date,	Code ( 8)	instr.	of Deriv Secu Acqu (A) o Dispo of (D (Instr and §	vative prities priced r osed ) r. 3, 4	Expiration Date (Month/Day/Ye		ate Year) Secui Undei Deriv: Secui 3 and		at of ties ying tive ty (Instr. I)  Amount or Number of	Derivative Security (Instr. 5) Beneficia Owned Following Reported		e Ownersh s Form: ally Direct (D) or Indirect g (I) (Instr.		Beneficial Ownership ct (Instr. 4)
	Christin  (Find BIOSCIE  MIDDLEFII  TAIN  (Since Security (Insert Stock  1 Stock  2.  Conversion of Exercise  Price of Derivative	(First) (In the price of Derivative (Month/Day/Year)	(First) (Middle) M BIOSCIENCES, INC. MIDDLEFIELD ROAD  TAIN CA 94043  (State) (Zip)  Table I - No Security (Instr. 3)  Table II  2. Conversion or Exercise Price of Derivative (Month/Day/Year) Price of Derivative (Month/Day/Year)	(First) (Middle)  M BIOSCIENCES, INC.  MIDDLEFIELD ROAD  TAIN CA 94043  (State) (Zip)  Table I - Non-Derivation (Month/Day)  Security (Instr. 3)  2. Transact Date (Month/Day)  1 Stock  Table II - Derivati (e.g., pt. (e.g., pt. (Month/Day)/Year)	(First) (Middle)  M BIOSCIENCES, INC. MIDDLEFIELD ROAD  TAIN CA 94043  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Stock  Table II - Derivative Security (e.g., puts, cate of Derivative Security (Month/Day/Year)  2. Transaction Date (if any puts, cate of Derivative Security (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  4. Transaction Date (Month/Day/Year)  3. Transaction Date (if any (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)	(First) (Middle)  M BIOSCIENCES, INC.  MIDDLEFIELD ROAD  Table I - Non-Derivative Security (Instr. 3)  Table II - Derivative Security (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year)  Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year)  2. Conversion or Exercise Price of Derivative Security (Month/Day/Year)  Security (Instr. 3)  A Deemed Execution Date, if any (Month/Day/Year)  Sa Deemed Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  Sa Deemed Execution Date, if any (Month/Day/Year)  (Month/Day/Year)	(First) (Middle)  (First) (Middle)  (First) (Middle)  (M	(First) (Middle)  (First) (Middle)  (A) (Middle)  (Middle)  (Middle)  (Middle)  (Middle)  (Middle)  (A) (Middle)  (A) (Middle)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Middle)  (Mid	Christina Teng   IGM Biosciences, Inc	(First) (Middle)  (First) (Middle)  (MIDDLEFIELD ROAD  Table I - Non-Derivative Securities Acquired, Dispecturity (Instr. 3)  Security (Instr. 3)  Table II - Derivative Securities Acquired, Dispecturity (Month/Day/Year)  Table II - Derivative Securities Acquired, Dispecturity (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired, Dispecturity (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired, Dispecturity (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired, Dispecturity (Month/Day/Year)  Security (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired, Dispecturity (Month/Day/Year)  Security (Month/Day/Year)  Date (Month/Day/Year)  Security (Instr. 3)  Transaction Code (Instr. 8)  Securities Acquired, Dispecturities Acquired (A) or Disposed of (D) (Instr. 8)  Date (Month/Day/Year)  Date (Month/Day/Year)  Date (Month/Day/Year)	(First) (Middle)  (First) (Middle)  (Middle)	Christina Teng   IGM Biosciences, Inc. [ IGMS ]   IGM Biosciences, Inc. [ IGMS ]	Christina Teng	Check all ap X Direct	Check all applicable   Check all applicable   Check all applicable   X Director	Check all applicables   Chec	Christina Teng   Check all applicable   X Director   X 10%

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy.
- 2. All shares are held directly by Haldor Topsoe Holding A/S (HTH). Jakob Haldor Topsoe, Christina Teng Topsoe, Anne Haugwitz-Hardenberg-Reventlow and Emil Oigaard, members of the board of directors of HTH, may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein, if any.

## Remarks:

/s/ Misbah Tahir, by power of attorney

10/04/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.